Deltanoid presses on with drug research
The end of a once promising partnership with Pfizer has not dissuaded a Madison biotechnology company from pursuing ways to bring drugs to market faster and more cost effectively. Deltanoid Pharmaceuticals, which was spun out of the University of Wisconsin-Madison, is pursuing Phase II funding...